|
Change of Director's Interest Notice
|
13 June 2023 at 9:25am
|
|
Mesoblast Director Appointed to Strategic Advisory Role
|
5 June 2023 at 10:05am
|
|
MSB Reports Q3 Financial Results and Operational Highlights
|
26 May 2023 at 8:55am
|
|
Third Quarter Results Presentation
|
26 May 2023 at 8:50am
|
|
Third Quarter Financial Results on Form 6-K
|
26 May 2023 at 8:45am
|
|
Mesoblast Third Quarter Financial Results Webcast
|
24 May 2023 at 6:30pm
|
|
Becoming a substantial holder
|
3 May 2023 at 9:40am
|
|
Change in substantial holding
|
3 May 2023 at 8:40am
|
|
Cleansing Notice
|
1 May 2023 at 5:45pm
|
|
Application for quotation of securities - MSB
|
28 April 2023 at 5:00pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 April 2023 at 10:50am
|
|
Reinstatement to Official Quotation
|
26 April 2023 at 10:15am
|
|
Proposed issue of securities - MSB
|
26 April 2023 at 10:15am
|
|
Mesoblast Completes Private Placement
|
26 April 2023 at 10:15am
|
|
Voluntary Suspension
|
24 April 2023 at 9:45am
|
|
Trading Halt
|
20 April 2023 at 11:20am
|
|
Pause in Trading
|
20 April 2023 at 11:00am
|
|
FDA Schedules GvHD Pre-License Manufacturing Inspection
|
22 March 2023 at 11:35am
|
|
Appendix 3G and Appendix 3H
|
15 March 2023 at 7:05pm
|
|
FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
8 March 2023 at 11:05am
|
|
Pause in Trading
|
8 March 2023 at 10:30am
|
|
Prospectus for Warrants Related to Oaktree Facility
|
3 March 2023 at 5:50pm
|
|
DREAM HF Trial Published in JACC
|
28 February 2023 at 8:40am
|
|
MSB Q2 Financial Results and Operational Highlights
|
28 February 2023 at 8:35am
|
|
Second Quarter Results Presentation
|
28 February 2023 at 8:25am
|
|
Half Yearly Report and Accounts
|
28 February 2023 at 8:25am
|
|
Mesoblast Second Quarter Financial Results Webcast
|
27 February 2023 at 11:45am
|
|
Remestemcel Clinical and Potency Studies Presented at Tandem
|
17 February 2023 at 10:15am
|
|
FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP
|
9 February 2023 at 10:00am
|
|
Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
|
1 February 2023 at 9:55am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 January 2023 at 6:50pm
|
|
Appendix 3G, Appendix 3H and Appendix 3Ys
|
16 January 2023 at 7:05pm
|
|
Biotech Showcase 2023 Presentation in San Francisco
|
10 January 2023 at 10:30am
|
|
Extension of Undrawn US$30 million Facility
|
23 December 2022 at 11:05am
|
|
Proposed issue of securities - MSB
|
23 December 2022 at 10:25am
|
|
Appendix 3G, Appendix 3H and Appendix 3Y
|
2 December 2022 at 8:00pm
|
|
Amended Constitution
|
24 November 2022 at 5:05pm
|
|
Results of Meeting
|
23 November 2022 at 4:30pm
|
|
Chairman's Address to Shareholders
|
23 November 2022 at 11:20am
|
|
Long-Term Survival for Acute GvHD Treatment with Remestemcel
|
23 November 2022 at 9:15am
|
|
MSB Q1 Financial Results and Operational Highlights
|
23 November 2022 at 9:10am
|
|
CEO First Quarter Results and 2022 AGM Presentation
|
23 November 2022 at 9:10am
|
|
First Quarter Financial Results on Form 6-K
|
23 November 2022 at 9:00am
|
|
Mesoblast First Quarter Financial Results Webcast
|
21 November 2022 at 6:05pm
|
|
Removal of Amendment to Constitution About Virtual Meetings
|
15 November 2022 at 9:50am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 October 2022 at 10:30am
|
|
Notice of Annual General Meeting and Proxy Form
|
24 October 2022 at 10:35am
|
|
Annual Report to Shareholders
|
24 October 2022 at 10:15am
|
|
Appendix 4G and Corporate Governance Statement
|
24 October 2022 at 10:00am
|
|
Notification of cessation of securities - MSB
|
14 October 2022 at 6:10pm
|
Mesoblast